Encorafenib for Small Bowel Adenocarcinoma or Appendiceal Adenocarcinoma With BRAF V600E Mutation


( Last Updated : August 30, 2021)
Project Line:
Reference List
Project Sub Line:
Reference List
Project Number:
RA1187-000

Details


Question

  1. ​ What is the clinical effectiveness of encorafenib in patients with small bowel adenocarcinoma or appendiceal adenocarcinoma with BRAF V600E mutation?
  2. What is the cost- effectiveness of encorafenib in patients with small bowel adenocarcinoma or appendiceal adenocarcinoma with BRAF V600E mutation?
  3. What are the evidence- based guidelines regarding the use of encorafenib for the treatment of patients with small bowel adenocarcinoma or appendiceal adenocarcinoma with BRAF V600E mutation?

Key Message

  • No evidence was identified regarding the clinical or cost- effectiveness of encorafenib in patients with small bowel adenocarcinoma or appendiceal adenocarcinoma with BRAF V600E mutation.
  • No evidence-based guidelines were identified regarding the use of encorafenib in patients with small bowel adenocarcinoma or appendiceal adenocarcinoma with BRAF V600E mutation.